AcuraStem Receives ALS Clinical Trial Award for AS-241
The ALS Association's $1 million award will fund biomarker development to support a Phase 1 first-in-human trial of AS-241, AcuraStem's UNC13A clinical candidate.
The ALS Association's $1 million award will fund biomarker development to support a Phase 1 first-in-human trial of AS-241, AcuraStem's UNC13A clinical candidate.